EMA Concludes Recombinant Factor VIII Medicines Pose No Greater Risk Of Inhibition
Executive Summary
The European Medicines Agency has found that recombinant and plasma-derived factor VIII medicines both pose the same level of risk regarding production of inhibitors in hemophilia patients. The agency has recommended changes to the package leaflets of these medicines to reflect current knowledge.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.